Key Takeaways
- GSK has committed to purchasing Nuvalent for $10.6 billion through an all-cash transaction at $124 per share — representing a 40% premium over Monday’s closing price
- Shares of GSK declined up to 3% during early London market hours after the acquisition announcement
- Nuvalent’s primary pipeline includes two therapies targeting non-small-cell lung cancer, both awaiting regulatory decisions from the FDA this year
- Revenue impact is projected for 2027, while core earnings per share benefits are anticipated beginning in 2029
- The pharmaceutical company maintains its 2026 full-year forecast of 7–9% core EPS expansion remains unchanged despite the acquisition
GSK has confirmed its intention to purchase Nuvalent through an all-cash transaction valued at $10.6 billion, offering $124 per share — marking a substantial 40% premium above Monday’s closing valuation.
GSK stock experienced a decline of as much as 3% during early London trading sessions following Tuesday’s announcement. Despite this dip, shares remain elevated approximately 23% compared to twelve months prior.
Nuvalent’s shares had faced headwinds throughout the current year, declining roughly 12% prior to the acquisition announcement, positioning its market capitalization near $7 billion.
This transaction represents the most significant acquisition under CEO Luke Miels’ leadership since he succeeded Emma Walmsley at the beginning of 2026. It marks his second major deal this year, coming after a $2.2 billion purchase of Rapt Therapeutics completed in January.
Financing for the transaction will primarily come from a combination of new borrowing facilities, existing debt instruments, and available cash reserves. The company has confirmed the deal structure won’t compromise its current credit rating.
Dual Late-Stage Cancer Treatments Join GSK Portfolio
Nuvalent’s flagship drug candidates are designed for non-small-cell lung cancer patients carrying specific genetic alterations — mutations predominantly found in non-smoking populations. Both therapies have advanced to late-stage clinical development and are currently under FDA review with decisions expected later in 2026.
According to GSK, both investigational drugs possess blockbuster sales potential upon regulatory approval. Additionally, the transaction provides GSK access to a development platform that could enhance its experimental antibody-drug conjugate Ris-Rez, which is currently undergoing late-stage evaluation.
Nuvalent specializes in developing precision-targeted oncology therapeutics. Its development pipeline aligns seamlessly with Miels’ strategic vision — building a more robust late-stage cancer drug portfolio.
GSK’s oncology division experienced 43% growth throughout 2025, reaching just under £2 billion, though it represents merely 6% of the company’s overall £32.7 billion revenue stream.
By comparison, competitor AstraZeneca derives 44% of its total revenues from oncology products. GSK faces considerable ground to cover in bridging this disparity, though this acquisition represents a meaningful stride toward that objective.
Addressing GSK’s Oncology Deficit — Lessons from AstraZeneca’s Success
GSK divested its oncology assets in 2014 through an asset exchange arrangement with Novartis. Conversely, AstraZeneca doubled down on cancer therapeutics under CEO Pascal Soriot’s leadership — a strategic bet that delivered substantial returns.
Miels previously served as an executive at AstraZeneca. His appointment was broadly interpreted as an indication that GSK intended to adopt elements of that successful strategy.
The Nuvalent transaction won’t alter GSK’s 2026 full-year outlook, which continues to project 7–9% core EPS growth. The company anticipates low single-digit earnings per share dilution spanning 2026 through 2028.
Revenue contributions are projected to materialize in 2027, with positive core EPS impact beginning in 2029. After accounting for acquired cash, GSK’s net investment totals approximately $9.4 billion.
Regulatory clearances permitting, the deal is slated to conclude during Q3 2026.
Miels has outlined ambitions to surpass £40 billion in annual revenue by 2031 while fortifying the pipeline in advance of the 2028 patent cliff for HIV medication dolutegravir.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
